What Happened to Ebola virus disease?
Ebola virus disease (EVD) is a severe, often fatal illness in humans and other primates, first identified in 1976. After the devastating 2014-2016 West Africa epidemic, significant strides were made in vaccine and treatment development for the Zaire ebolavirus strain. However, as of June 2026, the world is grappling with a challenging outbreak of the Bundibugyo ebolavirus in the Democratic Republic of Congo and Uganda, for which no approved vaccines or specific treatments currently exist, prompting an urgent global response to accelerate new countermeasures.
Quick Answer
Ebola virus disease continues to pose a significant global health threat, with the most recent major development being a severe outbreak of the Bundibugyo ebolavirus in the Democratic Republic of Congo (DRC) and Uganda, declared a Public Health Emergency of International Concern in May 2026. This strain lacks approved vaccines or specific treatments, unlike the more common Zaire ebolavirus. As of late June 2026, confirmed cases in the DRC have surpassed 1,100, with ongoing efforts to develop and trial new vaccines and therapeutics, while facing challenges from conflict and remote affected areas.
📊Key Facts
📅Complete Timeline14 events
Ebola Virus Disease First Identified
Ebola virus disease was first identified in two simultaneous outbreaks in Zaire (now DRC) and Sudan, near the Ebola River, from which the virus takes its name.
West Africa Ebola Epidemic Begins
The largest Ebola outbreak in history began in southeastern Guinea, eventually spreading to Liberia and Sierra Leone, and causing a global health crisis.
WHO Declares West Africa Outbreak a PHEIC
The World Health Organization declared the West Africa Ebola epidemic a Public Health Emergency of International Concern (PHEIC), underscoring its severity and international spread.
First Ebola Case Diagnosed in the United States
The first case of Ebola diagnosed in the United States was reported in a man who traveled to Dallas, Texas, from Liberia.
DRC Kivu Outbreak and Vaccine Deployment
The Democratic Republic of Congo experienced its 10th Ebola outbreak in North Kivu and Ituri provinces, during which the rVSV-ZEBOV vaccine (Ervebo) was deployed, marking a significant turning point in outbreak control.
Uganda Reports Sudan Virus Ebola Case
Ugandan health officials reported a confirmed case of Ebola caused by the Sudan virus, which was later declared over on April 26, 2025.
DRC Declares 16th Ebola Outbreak in Kasai Province
The DRC Ministry of Public Health declared its 16th Ebola outbreak in the remote Bulape health zone in Kasai Province, which was declared over on December 1, 2025.
Earliest Suspected Case of Current Bundibugyo Outbreak
The earliest known suspected case of the ongoing Bundibugyo ebolavirus outbreak in the DRC was a health worker who fell ill and died in Bunia, Ituri Province.
DRC and Uganda Declare Bundibugyo Ebola Outbreak
Both the Democratic Republic of Congo and Uganda officially declared an outbreak of Ebola virus disease caused by the Bundibugyo virus, following laboratory confirmation.
WHO Declares 2026 Bundibugyo Outbreak a PHEIC
The World Health Organization designated the ongoing Bundibugyo ebolavirus outbreak in the DRC and Uganda a Public Health Emergency of International Concern.
WHO Advises on Candidate Bundibugyo Treatments and Vaccines
Experts convened by the WHO recommended prioritizing several candidate therapeutics (MBP134, Maftivimab, remdesivir) and vaccines (IAVI, Oxford, Moderna candidates) for evaluation in clinical trials against the Bundibugyo virus.
Emergency Funding for Bundibugyo Vaccine Development
Three vaccine developers (IAVI, Oxford University, Moderna) received $60 million in emergency funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of Bundibugyo-specific vaccines.
DRC Cases Surpass 1,000; Treatment Trials Announced
Confirmed Ebola cases in the DRC surpassed 1,000, and the WHO announced clinical trials for two potential therapeutics, MBP134 and remdesivir, for the Bundibugyo strain.
Current Outbreak Status: Over 1,100 Cases in DRC
As of today, the ECDC reported 1,155 confirmed cases and 304 deaths in the DRC, and 20 confirmed cases and 2 deaths in Uganda, with ongoing international response efforts.
🔍Deep Dive Analysis
Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, emerged in 1976 with nearly simultaneous outbreaks in what is now the Democratic Republic of Congo (DRC) and Sudan. The virus, primarily hosted by fruit bats, transmits to humans through contact with infected animals and then spreads person-to-person via bodily fluids.
The disease gained global prominence during the 2014-2016 West Africa epidemic, the largest in history, which resulted in over 28,600 cases and approximately 11,300 deaths across Guinea, Liberia, and Sierra Leone. This crisis highlighted critical gaps in global health preparedness and spurred unprecedented international collaboration, leading to the accelerated development and eventual approval of the rVSV-ZEBOV vaccine (Ervebo) for the Zaire ebolavirus strain, which proved highly effective in subsequent outbreaks, such as the 2018-2020 epidemic in the DRC.
As of June 2026, the world is confronting a new and challenging EVD outbreak in the DRC and Uganda, caused by the Bundibugyo ebolavirus (BDBV). This 17th outbreak in the DRC began with suspected cases in April 2026 and was officially declared in May 2026, with the World Health Organization (WHO) designating it a Public Health Emergency of International Concern (PHEIC) on May 16-17, 2026. The Bundibugyo strain is particularly concerning because existing vaccines and treatments, effective against the Zaire strain, offer limited or no cross-protection.
The current outbreak has rapidly escalated, with the DRC reporting 1,155 confirmed cases and 304 deaths as of June 25, 2026, making it the third-largest Ebola outbreak on record by June 22. Uganda has also reported 20 confirmed cases and two deaths, with imported cases identified in France and a US citizen medically evacuated to Germany. Response efforts are hampered by the remote, conflict-affected regions where the virus is spreading, as well as community distrust and attacks on healthcare workers.
In response, the WHO and partners are expediting clinical trials for several candidate vaccines (from IAVI, Oxford University, and Moderna) and therapeutics (monoclonal antibodies MBP134 and Maftivimab, and the antiviral remdesivir) specifically targeting the Bundibugyo virus. Additionally, the oral antiviral obeldesivir is being evaluated for post-exposure prophylaxis. The United States has committed over $162 million in foreign assistance and established dedicated response clinics to support regional efforts. Despite these efforts, the absence of approved countermeasures for BDBV and the challenging operational environment make containment exceptionally difficult, with the current outbreak's trajectory significantly worse than previous ones at similar stages.
What If...?
Explore alternate histories. What if Ebola virus disease made different choices?